Outcome measures for trials of remyelinating agents in multiple sclerosis: Retrospective longitudinal analysis of visual evoked potential latency

Multiple Sclerosis

Volumn 15, Issue 1, 2009, Pages 68-74

  Niklas, A ^a   Sebraoui, H ^a   Hess E ^a   Wagner, A ^a   Then Bergh, Florian ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Clinical trials; Multiple sclerosis; Outcome measure; Remyelination; Visual evoked potentials

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; EVOKED VISUAL RESPONSE; FOLLOW UP; HUMAN; LATENT PERIOD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; OPTIC NEURITIS; OUTCOME ASSESSMENT; PROGNOSIS; REMYELINIZATION; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADULT; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; EVOKED POTENTIALS, VISUAL; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; OPTIC NEURITIS; REACTION TIME; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 58149083654     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508095731     Document Type: Article

References (29)

1. Patrikios P Stadelmann C Kutzelnigg A. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165-3172.
2. Patani R Balaratnam M Vora A Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 2007; 33: 277-287.
3. Lucchinetti C Brück W Parisi J Scheithauer B Rodriguez M Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122: 2279-2295.
4. Lucchinetti C Brück W Parisi J Scheithauer B Rodriguez M Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
5. Barkhof F Brück W De Groot CJ. Remyelinated lesions in multiple sclerosis: Magnetic resonance image appearance. Arch Neurol 2003; 60: 1073-1081.
6. Brück W Kuhlmann T Stadelmann C. Remyelination in multiple sclerosis. J Neurol Sci 2003; 206: 181-185.
7. Becker WJ Richards IM. Serial pattern shift visual evoked potentials in multiple sclerosis. Can J Neurol Sci 1984; 11: 53-59.
8. Jones SJ. Visual evoked potentials after optic neuritis. Effect of time interval, age and disease dissemination. J Neurol 1993; 240: 489-494.
9. Frederiksen JL Petrera J. Serial visual evoked potentials in 90 untreated patients with acute optic neuritis. Surv Ophthalmol 1999; 44(Suppl. 1): S54-S62.
10. Brusa A Jones SJ Plant GT. Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study. Brain 2001; 124: 468-479.
11. Hidajat RR Goode DH. Normalisation of visual evoked potentials after optic neuritis. Doc Ophthalmol 2003; 106: 305-309.
12. Poser CM Paty DW Scheinberg L. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
13. Polman CH Reingold SC Edan G. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
14. Hammond SR MacCallum S Yiannikas C Walsh JC McLeod JG. Variability on serial testing of pattern reversal visual evoked potential latencies from full-field, half-field and foveal stimulation in control subjects. Electroencephalogr Clin Neurophysiol 1987; 66: 401-408.
15. Romani A Bergamaschi R Versino M Zilioli A Callieco R Cosi V. Reliability and upper normal variability limits of pattern reversal visual evoked potential parameters. Boll Soc Ital Biol Sper 1992; 68: 573-580.
16. Rudick RA Cutter G Reingold S. The multiple sclerosis functional composite: A new clinical outcome measure for multiple sderosis trials. Mult Scler 2002; 8: 359-365.
17. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis. Neurology 2007; 68: S72-S82.
18. Stankoff B Wang Y Bottlaender M. Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A 2006; 103: 9304-9309.
19. Noseworthy JH O'Brien PC Petterson TM. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522.
20. Roed HG Langkilde A Sellebjerg F. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-810.
21. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): A study of 8 years of follow-up. Doc Ophthalmol 2005; 110: 91-102.
22. Taylor MJ Keenan NK Gallant T Skarf B Freedman MH Logan WJ. Subclinical VEP abnormalities in patients on chronic deferoxamine therapy: longitudinal studies. Electroencephalogr Clin Neurophysiol 1987; 68: 81-87.
23. Beblo S Reinhardt H Muntau AC Mueller-Felber W Roscher AA Koletzko B. Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 2001; 57: 1488-1491.
24. Mondelli M Sicurelli F Scarpini C Dotti MT Federico A. Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. J Neurol Sci 2001; 190: 29-33.
25. Hickman SJ Toosy AT Miszkiel KA. Visual recovery following acute optic neuritis - A clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004; 251: 996-1005.
26. Yang EB Hood DC Rodarte C Zhang X Odel JG Behrens MM. Improvement in conduction velocity after optic neuritis measured with the multifocal VEP. Invest Ophthalmol Vis Sci 2007; 48: 692-698.
27. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 2002; 3: 705-714.
28. Hohlfeld R Kerschensteiner M Meinl E. Dual role of inflammation in CNS disease. Neurology 2007; 68: S58-S63.
29. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol 2007; 17: 219-229.